Related MeSH Hierarchy (4)
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Gastroenteritis » Colitis » Colitis, Ulcerative
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Gastroenteritis » Inflammatory Bowel Diseases » Colitis, Ulcerative
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Intestinal Diseases » Colonic Diseases » Colitis » Colitis, Ulcerative
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Intestinal Diseases » Inflammatory Bowel Diseases » Colitis, Ulcerative
Description
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. MeSH
Hierarchy View
Approved Indicated Drugs (25)
Phase 4 Indicated Drugs (38)
Phase 3 Indicated Drugs (34)
Phase 2 Indicated Drugs (135)
Phase 1 Indicated Drugs (46)
Other Experimental Indicated Drugs (39)
Organization Involved with Phase 4 Indications (83)
Centro Hospitalar Lisboa Ocidental
European Crohn´s and Colitis Organisation
Foundation for liver and gut studies
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID)
Hospital Geral de Santo António
Hospital Provincial de Castellon
Hospital Universitario Arnau de Vilanova de Lleida
Huazhong University of Science and Technology
Istituto Clinico Humanitas - Rozzano (MI), Italy
Kliniken im Naturpark Altmuehltal
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Naturpark Kliniken Altmuehltal
Postgraduate Institute of Medical Education and Research
Schweizerische Morbus Crohnund Colitis ulcerosa Vereinigung
South-Eastern Norway Regional Health Authority
The Baruch Padeh Medical Center, Poriya
Organization Involved with Phase 3 Indications (94)
Asian Institute of Gastroenterology
Asian Institutes of Gastroenterology
German Federal Ministry of Education and Research
Institut National de la Santé Et de la Recherche Médicale, France
National University of Ireland
Nutrition Science Partners Limited
Pharmaceutical Research Associates, Inc. (PRA)
Organization Involved with Phase 2 Indications (158)
Academy of Science, Czech Republic
Aleris-Hamlet Hospitals Copenhagen
Azienda Ospedaliera San Giovanni Addolorata
Azienda Ospedaliera Sant'Andrea, Roma
Casa Sollievo della Sofferenza IRCCS
Catholic University of Sacred Heart, Rome
Crohn's and Colitis Foundation
Foundation for Clinical Research in IBD
Hamilton Health Sciences Corporation
Hemay Pharmaceutical PTY. LTD.
Holy Stone Healthcare Co., Ltd
Hoosier Cancer Research Network
Ivy Institute of Stem Cells Co. Ltd
JP Moulton Charitable Foundation
Katholieke Universiteit Leuven
Klinika Przewodu Pokarmowego Szpital Kliniczny Nr 1 - Lodz - Poland
Luigi Sacco University Hospital
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Natrogen Therapeutics International, Inc
Queen Elizabeth Hospital NHS Foundation Trust
Reistone Biopharma Company Limited
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
Santa Barbara Cottage Hospital
Sterna Biologicals GmbH & Co. KG
Technical University of Denmark
The Eli and Edythe Broad Foundation
The University of Texas, Dallas
Universitaetsklinikum Schleswig-Holstein
University Hospital of North Norway
University of British Columbia
University of California, San Diego
University of Erlangen-Nuremberg
University of Naples Frederico II
University of Roma La Sapienza
University of Rome Tor Vergata
University of Texas at Houston
Vancouver Island Health Authority
Western Norway Regional Health Authority
Organization Involved with Phase 1 Indications (29)
China Academy of Chinese Medical Sciences
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Organization Involved with Other Experimental Indications (31)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
